Insight Molecular Diagnostics (IMDX) Prepaid Assets (2016 - 2026)

Insight Molecular Diagnostics has reported Prepaid Assets for 11 years, with the latest figure at $1.0 million in Q1 2026.

• Quarterly Prepaid Assets fell 15.14% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 15.14% YoY) and the FY2025 annual result came in at $1.4 million, up 72.96% from the prior year.
• Prepaid Assets eased to $1.0 million in Q1 2026 per IMDX's latest filing, from $1.4 million in the prior quarter.
• Over five years, Prepaid Assets peaked at $2.2 million in Q3 2022 and troughed at $595000.0 in Q2 2024.
• A 5-year average of $1.1 million and a median of $1.0 million in 2026 frame the typical range for Prepaid Assets.
• The sharpest annual moves came in 2023 and 2025: Prepaid Assets plunged 69.09% in 2023, then soared 126.89% in 2025.
• Over 5 years, Prepaid Assets stood at $977000.0 in 2022, then slumped by 34.19% to $643000.0 in 2023, then climbed by 27.68% to $821000.0 in 2024, then soared by 72.96% to $1.4 million in 2025, then dropped by 26.2% to $1.0 million in 2026.
• According to Business Quant data, Prepaid Assets over the past three periods registered $1.0 million, $1.4 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.